Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Pharma stocks lead the gainers
Mon, 13 Jul 11:30 am

After opening the day on a flat note, the indices have not shown any major movement. Buying interest is seen in the Pharmaceutical sector.

The BSE-Sensex is trading up by 8 points (0.03%) and the NSE-Nifty is trading up by 6 points (0.06%). The S&P BSE Midcap index is trading up by 41 points (0.37%), while the S&P BSE Smallcap index is trading up by 74 points (0.65%). The rupee is trading at 63.47 to the US dollar. Gold and Silver are trading at Rs 26,082 per 10 grams & Rs 35,521 per kilogram respectively.

Stocks in Pharmaceutical sector are trading on a positive note with Cipla and Sun Pharma leading the winners. Dr Reddy's posted a good performance in the last fiscal. It has addressed the shareholders that their performance is going to improve in FY16. The reasons cited for the same are its expansion of generic business in North America and emerging markets becoming the main growth drivers, backed by the launch of new formulations. The company stated that they have 68 abbreviated new drug applications (ANDAs) filed for approval with the USFDA. Out of these filing 43 are Para IV fillings. The rest have the ‘First to File' status. Dr Reddy's is trading up by 0.5%.

Stocks in Banking sector are trading on a mixed note with Allahabad Bank trading down by 1% and Dhanlaxmi Bank trading up by 7.5%. The finance ministry has planned to pump Rs 120 bn into state owned banks. This is in addition to Rs 79.4 bn allocated in the budget towards capitalization. The funds will be allocated to the banks that are in urgent need of capital, even if they don't meet the efficiency criteria. Beneficiaries in the first infusion may include Syndicate Bank, Central Bank of India and Allahabad Bank. Capital infusion is required in the state owned banks as they have a lot of stressed assets on their balance sheet and in order to resume lending to provide support to the government's economic revival programme.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma stocks lead the gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.